Table 2.
Hazard ratios of the composite outcome of death or allograft loss according to natural log-transformed FGF23 (per 1 SD increase) and ascending tertiles of FGF23
| Natural log FGF23 |
FGF23 Tertiles |
|||||
|---|---|---|---|---|---|---|
| per 1 SD | P | 1 | 2 | 3 | Pa | |
| All patients, n = 984 | ||||||
| crude | 1.94 | <0.001 | Reference | 1.96 | 6.49 | <0.001 |
| 1.77, 2.13 | 1.19, 3.25 | 4.15, 10.1 | ||||
| eGFR | 1.61 | <0.001 | Reference | 1.40 | 3.04 | <0.001 |
| 1.43, 1.82 | 0.84, 2.33 | 1.89, 4.9 | ||||
| eGFR, age, gender | 1.62 | <0.001 | Reference | 1.34 | 2.84 | <0.001 |
| 1.43, 1.84 | 0.80, 2.24 | 1.76, 4.57 | ||||
| full model | 1.46 | <0.001 | Reference | 1.39 | 2.27 | <0.001 |
| 1.28, 1.68 | 0.83, 2.33 | 1.38, 3.72 | ||||
| full model + phosphate | 1.42 | <0.001 | Reference | 1.42 | 2.23 | 0.001 |
| 1.23, 1.62 | 0.85, 2.39 | 1.35, 3.67 | ||||
| full model + logPTH | 1.44 | <0.001 | Reference | 1.39 | 2.23 | 0.001 |
| 1.25, 1.65 | 0.83, 2.33 | 1.35, 3.66 | ||||
| Restricted to patients with eGFR 30 to 90 ml/min per 1.73 m2, n = 765 | ||||||
| crude | 1.63 | <0.001 | Reference | 1.75 | 3.96 | <0.001 |
| 1.37, 1.94 | 0.99, 3.12 | 2.32, 6.77 | ||||
| eGFR | 1.57 | <0.001 | Reference | 1.55 | 2.92 | <0.001 |
| 1.29, 1.92 | 0.87, 2.77 | 1.67, 5.05 | ||||
| eGFR, age, gender | 1.55 | <0.001 | Reference | 1.51 | 2.61 | <0.001 |
| 1.26, 1.90 | 0.85, 2.70 | 1.50, 4.54 | ||||
| full model | 1.43 | 0.002 | Reference | 1.57 | 2.24 | 0.005 |
| 1.14, 1.78 | 0.87, 2.80 | 1.27, 3.94 | ||||
| full model + phosphate | 1.45 | 0.001 | Reference | 1.57 | 2.29 | 0.004 |
| 1.17, 1.81 | 0.88, 2.81 | 1.30, 4.03 | ||||
| full model + logPTH | 1.42 | 0.003 | Reference | 1.54 | 2.18 | 0.007 |
| 1.13, 1.77 | 0.86, 2.76 | 1.23, 3.85 | ||||
Full model is adjusted for eGFR, age, gender, systolic BP, body mass index, albumin, calcium, Charlson score, and the duration after transplant at the time of enrollment.
aP for linear trend.